Novo Nordisk forlænger og udvider program for børn med type 1-diabetes i udviklingslande

BAGSVÆRD, Danmark, November 14, 2016 /PRNewswire/ —

Novo Nordisk har besluttet at forlænge sit Changing Diabetes® in Children-program med fire år – et program, som giver børn med type 1-diabetes i udviklingslande adgang til behandling og gratis insulin. Samtidig kommer fem nye lande med i programmet: Cambodia, Elfenbenskysten, Myanmar, Senegal og Sudan. Ambitionen er, at programmet i 2020 over en 11-årig periode har hjulpet flere end 20.000 børn.






For at se vores Multimedia News Release, venligst besøg:

https://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes

For 10 år siden var den forventede levetid for et barn med type 1-diabetes i afrikanske lande syd for Sahara ofte mindre end et år[1]. Det fik Novo Nordisk til at etablere Changing Diabetes® in Children-programmet, som skal bidrage til at forbedre kvaliteten af behandlingen og mulighederne for at diagnosticere sygdommen. Siden programmet blev etableret i 2009, har 13.700 børn i ni lande i Afrika og Sydøstasien haft adgang til diabetesbehandling og gratis human insulin.

“Changing Diabetes® in Children-programmet har været ikonisk,” siger professor Azad Khan, formand for Diabetic Association of Bangladesh. “Det har ændret tilværelsen for børn med type 1-diabetes i Bangladesh. Deres overlevelse er afhængig af, at de får insulin og bliver undervist i, hvordan de skal håndtere sygdommen. Alt dette sørger programmet for.”

Et stort antal børn i programmet har nu fået deres diabetes under kontrol, så de kan leve et godt og sundt liv. Indtil nu er der etableret 108 klinikker, og flere end 7.000 læger og andet sundhedspersonale er blevet undervist i diabetesbehandling.

Udover at donere gratis insulin har Changing Diabetes® in Children-programmet til formål at støtte udviklingen af de lokale sundhedssystemer. Lars Rebien Sørensen, administrerende direktør for Novo Nordisk, siger: “Udlevering af gratis medicin kan ikke i sig selv løse komplekse sundhedsmæssige udfordringer. Lige fra vi lancerede programmet, har vi derfor arbejdet tæt sammen med lokale partnere om at levere bæredygtige behandlingsløsninger sammen med insulinen for at forbedre tilværelsen for børn med type 1-diabetes både nu og i fremtiden.”

Om Changing Diabetes® in Children 

De globale partnere i programmet er Novo Nordisk, Roche, International Society for Pediatric and Adolescent Diabetes (ISPAD) og Verdensdiabetesfonden (WDF). I hvert af de ni lande, der allerede deltager (Cameroun, Den Demokratiske Republik Congo, Etiopien, Guinea, Kenya, Tanzania, Uganda, Bangladesh og Indien), drives programmet som et privat-offentligt partnerskab med en gruppe lokale samarbejdspartnere. Landenes sundhedsministerier spiller en afgørende rolle i at sikre, at Changing Diabetes® forankres i det eksisterende sundhedssystem.

Referencer 

1. Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043  

Yderligere information 


   
    Medier:
    Charlotte
    Zarp-Andersson     +45-4442-7603  czpa@novonordisk.com

    Investorer:
    Peter Hugreffe
    Ankersen           +45-3075-9085  phak@novonordisk.com
    Hanna Ögren        +45-3079-8519  haoe@novonordisk.com
    Anders Mikkelsen   +45-3079-4461  armk@novonordisk.com
    Melanie Raouzeos   +45-3075-3479  mrz@novonordisk.com

     (Logo: http://photos.prnewswire.com/prnh/20120911/559804 )

Video: 
     https://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes

SOURCE Novo Nordisk


satprnews.com

Nitto Avecia annonce plusieurs extensions relatives à la production d'oligonucléotides

MILFORD, Massachusetts, 14 novembre 2016 /PRNewswire/ — Nitto Avecia Inc. (Avecia), a fait part aujourd’hui des progrès de la société liés à l’extension de ses capacités de développement analytique et de production d’oligonucléotides. Cette annonce souligne la poursuite de la solide stratégie de croissance d’Avecia en vue d’accroître sensiblement sa capacité de production de substances pharmaceutiques d’oligonucléotides, à Milford (Massachusetts), mais aussi de produits pharmaceutiques à Irvine (Californie) et ses capacités de développement analytique à Irvine (Californie) et Marlboro (Massachusetts).

Avecia, un chef de file réputé dans le domaine de la production d’acide nucléique à des fins thérapeutiques, avance bien dans la construction d’un nouveau site de production de substances pharmaceutiques d’oligonucléotides, d’une capacité supplémentaire de plus de 1,5 mol. Plus tôt cette année, un nouveau synthétiseur de 300 mmol a été mis en service avec succès, augmentant les capacités opérationnelles de son actif à moyenne échelle. Il est prévu qu’en 2017, le site d’Avecia à Milford dispose d’une capacité de production de près de 3 mol de synthèse d’oligonucléotide aux normes cGMP en comptant les activités alignées situées en aval, ce qui en fait le site de production d’oligonucléotides aux normes cGMP le plus important au monde.






Selon Detlef Rethage, le président d’Avecia, la croissance à 300 mmol en 2016, suivie du nouveau site de production supérieur à 1,5 mol en 2017, permettra aux clients de recevoir en temps opportun les substances pharmaceutiques d’oligonucléotides pour faire avancer les programmes d’essais cliniques comme prévu. « Avecia s’enorgueillit du fait que grâce à l’expérience et l’innovation menées par Avecia, nos nouvelles unités de production voient le jour en quelques mois, plutôt qu’en quelques années », a déclaré Rethage.

Le laboratoire de développement analytique et le personnel occupent désormais une nouvelle installation de 6 500 pieds carrés (env. 604 m²) à Marlboro (Massachusetts). À l’installation de Marlboro s’ajoute Nitto Avecia Pharma Services, une nouvelle société créée suite à l’acquisition récente par Avecia d’Irvine Pharmaceutical Services (Irvine) et d’Avrio Biopharmaceuticals (Avrio). Nitto Avecia Pharma Services, basé à Irvine (Californie), a considérablement augmenté les capacités analytiques et l’appui à la production pharmaceutique d’Avecia. Rethage a révélé que : « Nitto Avecia Pharma Services est le parfait complément de nos services relatifs aux substances pharmaceutiques d’oligonucléotides et constitue une étape essentielle de notre stratégie de croissance. Le groupe Avecia fournit maintenant des services de développement et de production sur la côte Est, la côte Ouest et dans le Midwest pour notre site de production de Cincinnati. »  

Dans le cadre de sa prévision de croissance, Avecia prévoit de créer de nombreux emplois à plein temps au cours des trois prochains mois. Les nouveaux postes relèveront de la microbiologie, de la chimie analytique, de la production, de l’assurance qualité et du génie. Vous trouverez de plus amples informations sur les postes à pourvoir sur l’ensemble des sites de production d’Avecia en consultant www.aveciacareers.com

À PROPOS DE NITTO AVECIA INC.

Nitto Avecia Inc. est un chef de file réputé dans le domaine des services de développement et de production d’acide nucléique à des fins thérapeutiques, disposant de sites de production à Milford (Massachusetts) ; Marlboro (Massachusetts) ; et Cincinnati. La société propose ses services pour des thérapies à base d’ADN, d’ARN et d’autres oligonucléotides allant de l’échelle du milligramme au stade préclinique, à plus de 1 000 kg pour le lancement après commercialisation. Pour plus d’information : www.Avecia.com. Nitto Avecia est fier de faire partie de Nitto Group. Pour plus d’information : www.Nitto.com

À PROPOS DE NITTO AVECIA PHARMA SERVICES INC.

Nitto Avecia Pharma Services est votre solution unique en termes d’élaboration de contrats et de services de production de premier ordre. Nitto Avecia Pharma Services soutient les secteurs pharmaceutique, biopharmaceutique et des dispositifs médicaux à travers un ensemble complet de services reposant sur les bonnes pratiques de fabrication appliquées aux États-Unis (cGMP), notamment la pré-formulation/formulation, la fabrication parentérale, le développement analytique, le développement biopharmaceutique, la chimie structurale, la chimie analytique, la microbiologie, la stabilité de stockage et l’essai de dispositifs d’administration de médicaments. Grâce à trois installations ultramodernes se trouvant sur un site à Irvine (Californie), le personnel chevronné et les solides infrastructures de Nitto Avecia Pharma Services offrent des solutions centrées sur le client pour la gestion du cycle de vie, du stade initial jusqu’à l’après commercialisation. Apprenez-en davantage sur le site www.aveciapharma.com

Logo : http://photos.prnewswire.com/prnh/20161110/438178LOGO

Logo : http://photos.prnewswire.com/prnh/20161110/438179LOGO

SOURCE Nitto Avecia Inc.

Related Links


http://www.avecia.com


satprnews.com

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

PRINCETON, N.J. and LUND, Sweden, Nov. 14, 2016 /PRNewswire/ — America’s opioid crisis is taking the life of a person every 19 minutes. Responding to this crisis, Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) are pleased to announce positive top-line results from a pivotal Phase 3 randomized, double-blind, double-dummy, active controlled trial of weekly and monthly injections of buprenorphine (CAM2038) for treatment of moderate-to-severe opioid use disorder. In addition to achieving the primary endpoint of non-inferiority versus daily sublingual buprenorphine/naloxone (current Standard of Care), CAM2038 also demonstrated superiority for the key secondary endpoint.

“We are pleased with these significant clinical trial results, which show that our CAM2038 injectable buprenorphine products, if approved, can provide effective new solutions for patients and physicians,” said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. “Opioid addiction is an overwhelming public health epidemic. In the United States alone, there are 2.6 million patients diagnosed with opioid addiction, and approximately 30,000 people die every year from opioid overdoses. CAM2038 comes in both weekly and monthly formulations, each in a range of dosage strengths, in alignment with clinical practice of treating opioid addiction, where different patients have different and evolving needs as they progress from treatment initiation to stabilization and eventually long-term maintenance. We believe that our CAM2038 products, together with our recently approved Probuphine 6-month buprenorphine implant, have the potential to transform the treatment of opioid addiction.”






In the Phase 3 study enrolling 428 patients with opioid use disorder, CAM2038 achieved the main objective of statistical non-inferiority compared to the active comparator of SL BPN/NX for both the FDA and the EMA specified endpoints of responder rate (RR) (CI -3.5%, 10.4%; p<0.001) and percent negative urine samples for opioids (CI -0.2%, 13.7%; p<0.001), respectively.

Importantly, while this Phase 3 study was designed and powered for assessing non-inferiority, the protocol also planned to test superiority against SL BPN/NX based on the pre-defined secondary endpoint of cumulative distribution function (CDF) of the percent urines negative for opioids combined with self-reports for weeks 5 through 24.  The superiority of CAM2038 over SL BPN/NX was established with p=0.004.  

The retention rate in the trial was approximately 57.5% and, as expected, similar across both treatment arms. The overall safety profiles were comparable between the two treatment groups, with few serious adverse events (SAEs) reported for the CAM2038 and SL BPN/NX (3.2% vs 6.0%, respectively). There were no reported overdoses in the CAM2038 arm compared to 4 non-fatal overdoses (3 on heroin, one on Klonopin) in the SLBPN/NX arm. Injection site reactions occurred in 19% of the CAM2038 participants vs 22% of the SL BPN/NX participants. Seventy-four percent of the injection site reactions were reported as mild, 26% as moderate, and none were reported as severe.

“The positive results of this pivotal head-to-head Phase 3 study represent an important breakthrough for our weekly and monthly CAM2038 products for treatment of opioid dependence, as well as confirmation of the strength and applicability of our proprietary FluidCrystal® technologies and pipeline,” said Dr. Fredrik Tiberg, President and CEO of Camurus. “The results of this rigorous evaluation of CAM2038 compared to standard of care provide strong support for our upcoming market authorization applications. The demonstrated robust treatment effect of CAM2038 versus daily sublingual buprenorphine further underscores the potential to significantly improve treatment outcomes, in addition to avoiding the complications and risks associated with current daily medications.”

Given the successful results from this pivotal Phase 3 trial and the previously reported Phase 2 opioid challenge study, Braeburn and Camurus look forward to working expeditiously with the FDA and EMA to begin the submission process to bring this potentially transformative new treatment to the many patients living with opioid use disorder in the U.S., Europe and other parts of the world. The FDA has granted Fast Track designation for CAM2038 subcutaneous injectable products for the treatment of opioid addiction.

“A weekly buprenorphine injection would be an attractive option for initiation, early treatment, and treatment of unstable patients, where weekly medical visits are common, whereas a monthly injection is an attractive option for longer term maintenance treatment where monthly visits are common practice,” said Dr. Edward Nunes, MD, Professor of Psychiatry at Columbia University Medical Center and Investigator in the study.”

According to Dr. Michelle Lofwall, Assoc. Professor of Behavioral Science and Psychiatry at the University of Kentucky Center on Drug and Alcohol Research and Primary Investigator in the study, “If approved, the CAM2038 weekly and monthly injectable buprenorphine medications can improve how we treat opioid addiction and decrease the stigma associated with the medication that is in large part due to concerns about non-adherence and diversion. Together with the six-month buprenorphine implant, these new long-acting medication delivery systems would allow us to administer a proven medication to the patients directly, ensuring adherence which leads to improved medication efficacy as demonstrated in this trial as well as avoiding the potential for missed or stolen doses, diversion or accidental pediatric exposure, which are significant public health concerns.”

“Buprenorphine is a remarkably efficacious medication for treatment of opioid dependence, but in practice its effectiveness is limited by poor adherence,” added Dr. Nunes. “It is all too easy for patients to miss daily doses of buprenorphine pills or strips, and then relapse.  A long-acting injection, such as CAM2038, circumvents the need for daily pill taking and has the potential to substantially improve adherence and treatment outcomes.  In our experience, the CAM2038 injections were easy to administer and well-tolerated by patients. It should be easy to implement in a wide range of office, clinic, or hospital-based practices.” 

About the Phase 3 trial

The present Phase 3 trial was a multicenter, randomized, double blind, double dummy, active controlled study that enrolled a total of 428 patients at 36 U.S. sites with moderate to severe opioid use disorder (DSM–5 criteria; American Psychiatric Association, 2013). 

To meet enrollment criteria, participants could not be receiving treatment at the start of the study, but were seeking medication assisted treatment for opioid use disorder. Following randomization, participants underwent initiation with buprenorphine (BPN) treatment with either sublingual SL BPN/NX tablets (Group 1) or with CAM2038 q1w (Group 2). This is the first Phase 3 trial where patients are initiated with an injectable buprenorphine product, after a single oral test sublingual tablet, and without the benefit of a “stabilization phase.” After one week, Group 1 continued with daily SL BPN/NX and Group 2 with weekly CAM2038 for the following 11 weeks (Phase 1). Subjects were then transitioned to Phase 2 for the subsequent 12 weeks whereby Group 1 continued daily treatment with SL BPN/NX, while subjects in Group 2 (previously receiving weekly CAM2038 q1w) were switched to monthly injections with CAM2038 q4w.

The primary objective of this trial was to demonstrate the non-inferiority (NI) of CAM2038 compared with sublingual buprenorphine among adult patients with Opioid Use Disorder. The primary efficacy variable used for FDA was the responder rate in both Phase 1 and 2 of the trial. To be a responder for Phase 1, the patient must have had no evidence of illicit opioid use at Week 12 and have no evidence of illicit opioid use for at least two out of the three weeks from Week 9 to Week 11, inclusive. To be a responder for Phase 2, the patient must have demonstrated no evidence of illicit opioid use at Month 6 and no evidence of illicit opioid use in five out of the six illicit opioid use assessments in Phase 2. To meet the definition of a responder for the full trial, participants needed to meet responder criteria for both Phases 1 and 2. The primary efficacy variable used for EMA was mean percent of urines negative for opioids. The trial’s key secondary efficacy endpoint was a superiority testing of the cumulative distribution function (CDF) of urine samples negative for illicit opioids, verified with self-report.

The overall safety profile was comparable between the two treatment groups, with few serious adverse events (SAE’s) reported for the CAM2038 and SL BPN/NX (3.2% vs 6%, respectively). There were no reported overdoses in the CAM2038 arm, compared to 4 overdoses in the SL BPN/NX. There was one death due to a traffic accident in the CAM2038 arm. Complete results of the study will be presented at an upcoming scientific conference.

About Opioid Use Disorder (OUD) and Treatment

Opioid-involved overdose deaths are a public health epidemic, resulting in about 30,000 deaths in the United States in 2015. These deaths were caused by prescription-drug misuse and a rise in heroin use (twenty and ten thousand respectively). Opioids kill more people than firearms and car accidents. In Europe, it is estimated that over 70,000 lives were lost to drug overdoses in the first decade of the twenty-first century. Reducing drug-related deaths therefore remains a major challenge for public health policy.

12.5 million people misused opioid pain relievers and over 800,000 people used heroin in the United States in 2015. In 2013, prescription opioid abuse accounted for an estimated $78.5 billion in U.S. health and social costs. Despite the extreme high social costs and large patient population with opioid addiction, only about half of the estimated 2.6 million and 1.3 million people diagnosed with opioid addiction in the United States and Europe receive treatment medication.

Opioid use disorder is diagnosed by signs and symptoms of compulsive and harmful (psychologically, socially, physically) ongoing use of opioids even when there is a strong desire to cease their use.  Cravings or desire for use and painful opioid withdrawal symptoms can be overwhelming. There are clear changes in the brain involved with cognition, memory, rewards in both conscious and unconscious circuits that underlie opioid addiction.

Buprenorphine maintenance treatment is currently considered a gold standard for opioid use disorder treatment with more than one million patients receiving buprenorphine in the U.S. and Europe. The medication reduces cravings, reduces the risk of relapse, reduces fatalities from opioid overdose, and decreases injection drug behaviors associated with spread of infectious diseases such as hepatitis C and HIV. Currently, most patients on buprenorphine take daily doses. These forms of the medication are sometimes misused, abused and diverted or accidentally ingested by children. In addition, patients can inadvertently or intentionally miss doses, which makes them vulnerable to relapse and overdose death.

About CAM2038 Products

CAM2038 are buprenorphine subcutaneous investigational new drugs in late-stage clinical development for the treatment of opioid addiction. Once-weekly and once-monthly formulations have been developed, each with multiple doses, to allow individualized treatment of patients with opioid use disorder as part of a comprehensive treatment plan to include counseling and psychosocial support.

The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery and medication adherence to minimize the risks of diversion, abuse, misuse, and accidental exposure by children. Previously, the CAM2038 products were evaluated in four completed Phase 1/2 clinical trials. In addition to the study reported on today, there are two other ongoing clinical trials of CAM2038 in opioid addiction, a 48-week safety trial of weekly and monthly CAM2038 that is being conducted across 29 sites in the United States, Australia and Europe, and a Phase 2 trial to evaluate whether weekly and monthly CAM2038 can be expected to produce similar buprenorphine blood levels following administration at various injection sites. So far, more than 900 subjects have been enrolled in clinical studies evaluating CAM2038.

Design attributes of CAM2038 include small dose volumes of maximum about 0.6 mL (for the highest weekly dose) filled in prefilled syringes with a thin 23 gauge injection needle and administered subcutaneously, intended to minimize discomfort for patients, leading to enhanced patient and physician acceptance. CAM2038 is stored at room temperature, therefore avoiding the need for cold chain distribution and refrigerator storage, which most healthcare provider offices do not have. As CAM2038 is provided ready for use in a prefilled syringe, no mixing steps or room temperature conditioning is required.

About Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn’s pipeline products are at various stages of clinical development and include CAM2038 weekly and monthly subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.

Media contacts:
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

Sherry Feldberg
MSLGROUP Boston
781-684-0770
braeburnpharma@mslgroup.com

Logo – http://photos.prnewswire.com/prnh/20150607/221301LOGO
Logo – http://photos.prnewswire.com/prnh/20141119/159732LOGO

 




satprnews.com

Vigilant Biosciences Announces New Distribution Partnership Agreements for OncAlert® Oral Cancer Product Line for Spain, Portugal and Germany

FORT LAUDERDALE, Fla. and DUSSELDORF, Germany, Nov. 14, 2016 /PRNewswire/ — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced exclusive multi-year distribution agreement for sales and marketing of its OncAlert® Oral Cancer product line in Spain, Portugal and Germany.

Vigilant Biosciences made the announcement in conjunction with the MEDICA Trade Fair, where the Company is showcasing its OncAlert Oral Cancer product line in Hall 16, booth #D04.



Vigilant Biosciences’ new distribution partners include the IVD distribution company Moldionics, S.L., for the distribution of the OncAlert Oral Cancer product line to the dental and medical markets in Spain and Portugal; and Concile GmbH for the distribution of the OncAlert Oral Cancer product line to the dental and media markets in Germany. As part of the new multi-year deals, the OncAlert Oral Cancer product line will be available to customers in these regions starting early 2017.

The Company has previously announced multiple distribution agreements throughout Europe, Latin America, Africa and Asia/Pacific. The new agreements will further expand Vigilant Biosciences’ reach throughout Europe and support the company’s goal to deliver accurate and cost-effective tools to aid clinicians in the detection and treatment of oral cancer.

“Throughout Spain and Portugal, millions of people are at risk for developing oral cancer,” said Iñigo Yandiola, Managing Director of Moldionics, S.L. “By using simple, non-invasive, and cost-effective tools to help aid in the detection of the disease in its earliest stages, dental and medical professionals will be able to improve outcomes for thousands of patients who develop oral cancer each year.”

“Oral cancer is a growing problem in our region and worldwide, particularly with the increase in HPV-related oral cancer,” said Franz Maier, Managing Director of Concile GmbH. “Having easy-to-use tools to aid in the detection of oral cancer earlier, when it is more treatable, will help us save lives. There is a clear need in the market for the OncAlert products.”

The World Health Organization (WHO) estimates the 5-year prevalence of head and neck cancer to be 29,950 in Spain, 8,250 in Portugal and 70,900 in Germany. In addition, according to WHO reports, more than 21.48 million people in Spain, 5.51 million in Portugal and 35.38 million in Germany are at risk for oral cancer due to factors inducing smoking, heavy drinking and having been diagnosed with HPV – all key risk factors for oral cancer.

“Vigilant Biosciences is pleased to announce that we have further expanded the distribution of the OncAlert product line with these recent agreements,” said Matthew H.J. Kim, Founder, Chairman and CEO of Vigilant Biosciences. “As we have seen global oral cancer rates on the rise in recent years, early-stage detection has become increasingly more critical. With the help of our partners like Moldionics and Concile GmbH, we will be able to provide an easy-to-use, accurate and cost-effective way to aid in the detection of the disease in its earliest stages, to help impact deaths from this disease.”

About the OncAlert Oral Cancer Product Line
Vigilant Biosciences OncAlert Oral Cancer product line is based on patented technology that measures soluble CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient.  The OncAlert Oral Cancer product line currently includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus).

About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. For those who survive oral cancer diagnosed in the later stages, the treatment is painful, debilitating and often disfiguring. In addition, patients often struggle with eating and drinking, communicating and self image. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.

For more information or to set up a meeting with Vigilant Biosciences at MEDICA, please contact Jennifer Moritz at jmoritz@0to5.com.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark™ Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.

About Moldionics
Moldionics is a biotechnology company that specializes in the distribution of ready-to-use reagents for the in-vitro diagnostics. Moldionics is dedicated to leading clinical diagnostic laboratory techniques – ranging from the traditional cell cultures to the most innovative developments in the field of molecular biology.

About Concile GmbH
Concile GmbH develops, produces and distributes innovation medical rapid tests for the diagnosis of various diseases. The Company’s focus is to provide meaningful, quantifiable and economical rapid tests that can be used by medical professionals in the field.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and the OraMark™ Test by OncAlert Labs include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark Test is a Laboratory Developed Test (LDT) that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.

PR00-0009

 


satprnews.com

Novo Nordisk Expands Programme to Reach 20,000 Children with Diabetes in Developing Countries

Bagsværd, Denmark, 14 November 2016 ­– Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.

Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.

“The Changing Diabetes® in Children programme has been iconic,” says Professor Azad Khan, president of the Diabetic Association of Bangladesh. “It has changed the lives of children with type 1 diabetes in Bangladesh. Their survival depends on the supply of insulin as well as education on how to cope with diabetes, and the programme provides all of this.”

A large number of children enrolled in the program are experiencing good control and have a chance to lead healthier lives. To date, 108 clinics have been established and more than 7,000 healthcare professionals have been trained in diabetes care.

In addition to providing access to insulin, the Changing Diabetes® in Children programme aims to support the development of sustainable healthcare systems. Lars Rebien Sørensen, president and CEO of Novo Nordisk, expressed: “The provision of free medicine alone doesn’t solve complex healthcare challenges. From the outset of this programme, we have therefore worked closely with local partners to deliver sustainable solutions alongside insulin to improve the lives of children with type 1 diabetes both now and in the future.”

About Changing Diabetes® in Children
The global partners in the programme are Novo Nordisk, Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In each of the nine already established countries (Cameroon, Democratic Republic of Congo, Ethiopia, Guinea, Kenya, Tanzania, Uganda, Bangladesh and India), the programme is implemented as a public-private partnership with a group of local partners. The national ministries of health in these countries play a key role to ensure that Changing Diabetes® in Children is anchored within the existing healthcare system.

Further information

References

1Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006 http://www.sciencedirect.com/science/article/pii/S0140673606697043


satprnews.com

LCG to Sponsor World No. 3 Ranked Tennis Pro, Stan Wawrinka

LONDON, November 14, 2016 /PRNewswire/ —

London Capital Group, one of the leading online brokerage firms, has announced a four-year global partnership with world No. 3 ranked Swiss professional tennis player Stan Wawrinka.






     (Logo: http://photos.prnewswire.com/prnh/20160929/413493LOGO )

     (Photo: http://photos.prnewswire.com/prnh/20161110/437995 )

Wawrinka’s sponsorship deal takes effect from today, and he will begin promoting the LCG brand at the Barclays ATP World Tour Finals, to be held at London’s O2 from Sunday 13th to Sunday 20th November 2016.

Wawrinka is a three-time Grand Slam tournament winner. He has also won a gold medal for Switzerland at the 2008 Olympics in Beijing and is a 2014 Davis Cup champion.

Stan Wawrinka said: “I am overjoyed to have partnered with a globally recognised name like LCG. They have put their full confidence behind me and I’m very excited to work with them as I start this new phase of my career.”

Charles Henri Sabet, London Capital Group CEO, says: “We are extremely pleased to have Stan Wawrinka as LCG’s global brand ambassador. He is such a talented athlete and an inspirational figure whose career journey has been characterised by hard work and dedication.”

He added, “London Capital Group and Wawrinka share a common passion to achieve and maintain excellence in our respective fields. His unwavering commitment to his sport, make him an ideal partner for us. He is an individual who embodies the values of our company, which is why we consider this partnership much more than just branding.”

There are many similar skills required to achieve success in our business or as a tennis player. Traders need to be focused and disciplined, but have the courage to take a risk.  Equally, they must respect the volatility of the markets. Stan must demonstrate this same discipline and commitment to training, to know his competition and prepare well. As he is a role model in tennis, we are role models for the online trading industry

With over 20 years in the industry, London Capital Group offers over 5,000 markets including forex, shares, indices, commodities and options. LCG offers two trading platforms, advanced LCG Trader and MT4. The company has won numerous awards for innovation, technology and service. Based in London, LCG is listed on the London Stock Exchange and authorised and regulated by the Financial Conduct Authority (FCA).

Notes to Media 

About LCG http://www.lcg.com

With almost two decades in the business of online trading, you can rest assured that you’re trading with an experienced, globally recognised name that is here to stay. LCG is publicly listed on the London Stock Exchange, Authorised and regulated by the Financial Conduct Authority and operates under the very strictest standards and practices. 

London Capital Group Holdings plc (LCGH plc) is a company registered in England and Wales under registered number: 05497744. London Capital Group LTD (LCG) is a wholly owned subsidiary of LCGH plc. LCG is authorised and regulated by the Financial Conduct Authority (FCA) under the company’s registration number of: 182110. LCG is a member of the London Stock Exchange and is registered under company number: 3218125. Registered address for LCGH plc and LCG is: 1 Knightsbridge, London, SW1X 7LX.

If you would like additional information in regards to this press release please don’t hesitate to contact the marketing department at marketing@lcg.com

http://go.lcg.com/visit/?bta=35390&nci=6615&utm_source=sponsorship&utm_medium=Text%20Link&utm_content=Homepage&utm_campaign=press_release

SOURCE London Capital Group, lcg.com


satprnews.com

artegic Joins the Location Based Marketing Association

BONN, Germany, November 14, 2016 /PRNewswire/ —

Digital CRM consulting and technology provider artegic AG is joining the Location Based Marketing Association (LBMA). With the development of its own technologies and practical cases in location-based marketing and proximity marketing, artegic is an innovative driver for digital best-in-class dialogue marketing. With its membership in the LBMA, artegic is keen to expand its involvement. 






The Location Based Marketing Association is an international association with the aim of supporting research, education and innovation in location-based communication and services. The goal is simple: Inform, exchange, instruct. This promotes the use and establishment of new services and offers of our member companies. Members of the LBMA include retailers, agencies, advertisers, media, software and service providers as well as mobile phone companies. Worldwide, there are 1200 active companies in the association.

Proximity Marketing – Important Part of Customer-centred Communication 

Users nowadays are expecting a best-in-class experience in marketing and service: customer-centred, cross-channel, quick response to real time, context-sensitive, highly individualised and relevant at the right moment. Location-based marketing and especially proximity marketing take on an important role here. Proximity marketing identifies mobile users and responds in real time to mobile triggers (e.g. a change in location) with location-based and context-sensitive communication. Event venue provider Weser-Ems-Hallen, for example, uses an app developed by artegic and task communication to send out location-based restaurant vouchers and was thus able to increase the length customers stay at a venue. Proximity marketing is only at the beginning of its development, many scenarios are today only possible via an app, but this is bound to change in the near future.

Carsten Szameitat, CEO of the LBMA DACH says: “We are happy to welcome artegic as the newest member of the Location Based Marketing Association. As an international association, our goal is to promote research, education and innovation at the crossroads of man, location and media. A marketing specialist like artegic who focusses on customer-centred dialogue marketing perfectly fits our criteria with its more then 10 years of experience in marketing engineering. We look forward to our collaboration.”

“Today, customer-centred marketing towards mobile users needs to take into consideration the user context and especially the user location. This applies in the real-time response to mobile triggers. Modern proximity marketing technologies like those of artegic must be able to precisely identify the location of a user even indoors and immediately output suitable communication measures via app push, SMS or mobile messenger. Proximity marketing and location-based marketing are very young disciplines and still offer a lot of room for innovative, new applications. We look forward to promoting these developments together with the Location Based Marketing Association”, says Stefan von Lieven, CEO at artegic AG.

Download 

•    Logo artegic (JPG)

•    Logo artegic (EPS)

•    Logo Location-Based Marketing Association (JPG)

•    Portrait Stefan von Lieven (JPG)

•    Portrait Carsten Szameitat (JPG)

•    Photo von Lieven and Szameitat (JPG)

artegic AG – Know-how and Technology for Online CRM

artegic AG supports companies in the construction of loyal and profitable B-to-B and B-to-C customer relations via online channels. Our service portfolio includes strategic consulting, technologies and business services for online CRM and dialogue marketing via email, mobile and social media.

With the online CRM technology ELAINE FIVE, artegic offers a unique high-performance solution for the comprehensive realisation of campaigns, as well as marketing automation based on self-sharpening analytical customer profiles. artegic received the eco Internet Award for its trend-setting implementation of data privacy requirements.

Internationally, each month, approximately 2.7 billion emails, SMS and social media messages are sent via ELAINE FIVE. As an associated company of the Fraunhofer Gesellschaft, artegic draws on the know-how of the latter, as well as the expertise from long-standing best practice with renowned clients, such as RTL, PAYBACK, Web.de, REWE, maxdome, Hyundai and the German Federal Ministries of Finance and Justice.

artegic is certified company-wide by TÜV Rheinland, according to the international standard for IT and Data Decurity ISO/IEC 27001.

Your contact at artegic: 

Sebastian Pieper 
artegic AG
Zanderstrasse 7
53177 Bonn
Tel.: +49(0)228 22 77 97-57
pr@artegic.de

SOURCE artegic AG


satprnews.com

Novo Nordisk expande programa para alcançar 20.000 crianças com diabetes em países em desenvolvimento

SÃO PAULO, 14 de novembro de 2016 /PRNewswire/ — A Novo Nordisk acaba de anunciar uma extensão de quatro anos em seu programa Changing Diabetes® in Children (Mudando o Diabetes em Crianças, em português), que fornece acesso ao tratamento do diabetes e insulina gratuita para crianças com diabetes tipo 1 em países em desenvolvimento. A expansão inclui cinco novos países no programa – Camboja, Costa do Marfim, Mianmar, Senegal e Sudão -, com o objetivo de beneficiar, até 2020, mais de 20.000 crianças quando terão decorridos 11 anos do programa.

Para visualizar o Comunicado à Imprensa Multimídia, favor clicar em:
https://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes



Dez anos atrás, a expectativa de vida de uma criança da África Subsaariana com diabetes tipo 1 era de menos de um ano¹. Em resposta, a Novo Nordisk estabeleceu o programa Changing Diabetes® in Children para apoiar melhorias no diagnóstico e acesso a tratamentos de qualidade sustentáveis. Desde o início do programa, em 2009, 13.700 crianças em nove países da África e do Sudeste Asiático receberam insulina humana e acesso ao tratamento do diabetes de forma gratuita.

“O programa Changing Diabetes® in Children foi icônico”, afirma o Professor Azad Khan, presidente da Associação de Diabéticos de Bangladesh. “A sobrevivência dessas crianças depende do fornecimento de insulina e de educação sobre como lidar com o diabetes, e o programa fornece tudo isso. Com ele, foi possível mudar a vida de crianças com diabetes tipo 1 em Bangladesh.”

Um grande número de crianças inscritas no programa conseguiu controlar o diabetes e passou a viver de forma saudável. Até o momento, nos países participantes do programa, 108 clínicas foram estabelecidas e mais de 7.000 profissionais de saúde foram treinados para o tratamento adequado do diabetes.

Além de fornecer acesso à insulina, o programa Changing Diabetes® in Children tem por objetivo apoiar o desenvolvimento de sistemas sustentáveis de cuidados com a saúde. Lars Rebien Sørensen, presidente e CEO da Novo Nordisk, afirma: “Somente o fornecimento gratuito de medicamentos não resolve os complexos desafios dos cuidados com a saúde. Desde o início desse programa, temos trabalhado de perto com parceiros locais para fornecermos soluções sustentáveis juntamente com a insulina, a fim de melhorar a vida das crianças com diabetes tipo 1 tanto agora quanto no futuro”.

Sobre o programa Changing Diabetes® in Children 

Em cada um dos nove países já estabelecidos (Camarões, República Democrática do Congo, Etiópia, Guiné, Quênia, Tanzânia, Uganda, Bangladesh e Índia), o programa é implementado como uma parceria público-privada com um grupo de parceiros locais. Os ministérios nacionais de saúde destes países têm um papel chave para assegurar que o Changing Diabetes® in Children faça parte do sistema de saúde já existente. Além da Novo Nordisk, Roche, International Society for Pediatric and Adolescent Diabetes (ISPAD) e a World Diabetes Foundation (WDF) são parceiros globais do programa.

Referências 

1. Beran, Yudkin, Diabetes care in sub-Saharan Africa, 2006. Available at: www.sciencedirect.com/science/article/pii/S0140673606697043

Sobre a Novo Nordisk

A Novo Nordisk é uma empresa global de saúde com mais de 90 anos de inovação e liderança no tratamento do diabetes. Sua trajetória deu à companhia a experiência e a capacidade necessárias para ajudar pessoas com outras condições crônicas sérias, como hemofilia, distúrbios do crescimento e obesidade. Sediada na Dinamarca, a Novo Nordisk emprega aproximadamente 42.300 pessoas em 75 países e comercializa seus produtos em mais de 180 mercados. Para mais informações, visite www.novonordisk.com.br, Facebook, Twitter, LinkedIn, YouTube.

Informações para a imprensa

Caroline Ferreira | caroline.ferreira@edelmansignifca.com | 11 3060-3367

Fernanda Nascimento | fernanda.nascimento@edelmansignifica.com | 11 3060-3152

Natália Souza | natalia.souza@edelmansignifica.com | 11 3060-3160

Logo: http://photos.prnewswire.com/prnh/20120911/559804 


satprnews.com

LCG patrocinará a Stan Wawrinka, número 3 del tenis profesional mundial

LONDRES, 14 de noviembre de 2016 /PRNewswire/ — London Capital Group, una de las principales firmas de trading en línea, ha anunciado una asociación global de cuatro años con el número 3 del tenis profesional del mundo, el suizo Stan Wawrinka.

(Logo: http://photos.prnewswire.com/prnh/20160929/413493LOGO)






(Foto: http://photos.prnewswire.com/prnh/20161110/437995)

El acuerdo de patrocinio entrará en vigencia a partir de hoy, y Wawrinka comenzará promocionando la marca LCG en las Barclays ATP World Tour Finals, que se celebrarán en el O2 de Londres desde el domingo 13 hasta el domingo 20 de noviembre de 2016.

Wawrinka ha ganado tres títulos de Grand Slam. También ganó una medalla de oro para Suiza en los Juegos Olímpicos de Beijing 2008 y es campeón de la Copa Davis 2014.

Stan Wawrinka declaró: “Estoy sumamente feliz por haberme asociado con un nombre de reconocimiento global como LCG. Ellos han depositado toda su confianza en mí y estoy muy entusiasmado por trabajar con ellos en esta nueva etapa de mi carrera”.

Charles Henri Sabet, CEO de London Capital Group, dijo: “Estamos muy complacidos de tener a Stan Wawrinka como embajador global de marca de LCG. Es un atleta muy talentoso y una figura inspiradora cuya carrera se ha caracterizado por el esfuerzo y la dedicación”.

Y agregó: “London Capital Group y Wawrinka comparten la pasión por alcanzar la excelencia y mantenerla, cada uno en su campo. Su compromiso inquebrantable con su deporte lo convierte en un socio ideal para nosotros. Stan encarna los valores de nuestra compañía, y por eso consideramos que esta asociación es mucho más que una simple estrategia de comercialización”.

“Hay muchas habilidades similares necesarias para el éxito en el tenis y el trading. Un trader debe mantenerse enfocado y ser disciplinado, pero también debe tener valor para correr riesgos, según las circunstancias del mercado. Del mismo modo, Stan debe demostrar esa misma disciplina y ese compromiso con el entrenamiento, para estar bien preparado y poder adaptarse a cualquier situación durante un partido. Él es un verdadero ejemplo en el tenis, y nosotros lo somos en el trading en línea”.

Con más de 20 años de experiencia en la industria, London Capital Group ofrece más de 5.000 mercados, incluso forex, acciones, índices, commodities y opciones. LCG ofrece dos plataformas de trading: LCG Trader avanzado y MT4. La compañía ha ganado numerosos premios por innovación, tecnología y servicio. LCG tiene sede en Londres, cotiza en la Bolsa de Valores de Londres, y está autorizada y regulada por la Financial Conduct Authority (FCA).

Notas para los medios

Acerca de LCG http://www.lcg.com

Con casi dos décadas de experiencia en trading en línea, usted puede tener la seguridad de que está negociando con un nombre experimentado y reconocido globalmente. LCG es una compañía que cotiza públicamente en la Bolsa de Valores de Londres, está autorizada y regulada por la Financial Conduct Authority (FCA), y opera bajo las normas y prácticas más estrictas.

London Capital Group Holdings plc (LCGH plc) es una compañía registrada en Inglaterra y Gales bajo el número 05497744. London Capital Group LTD (LCG) es una filial de LCGH plc. LCG está autorizada y regulada por la Financial Conduct Authority (FCA) bajo el número de registro 182110. LCG es miembro de la Bolsa de Valores de Londres y está registrada con el número 3218125. El domicilio registrado de LCGH plc y LCG es: 1 Knightsbridge, London, SW1X 7LX.

Si desea más información relacionada con este comunicado de prensa, no dude en ponerse en contacto con el departamento de Marketing en marketing@lcg.com





satprnews.com

Nitto Avecia kündigt mehrere Erweiterungen im Bereich Oligonukleotide an

MILFORD, Massachusetts, 14. November 2016 /PRNewswire/ — Nitto Avecia Inc. (Avecia) informierte heute über seinen Fortschritt beim Ausbau seiner Fähigkeiten für analytische Entwicklung und Oligonukleotid-Herstellung. Die Ankündigung signalisiert die Fortsetzung der robusten Wachstumsstrategie von Avecia, die Herstellungskapazität seiner oligonukleotiden Arzneimittelsubstanzen in Milford, MA, wesentlich zu erhöhen. Des Weiteren sollen weitere Arzneimittelkapazitäten in Irvine, CA, und analytische Entwicklungsfähigkeiten in Irvine, CA, sowie Marlboro, MA, hinzukommen.

Avecia, ein anerkannter, führender Hersteller von therapeutischen Nukleinsäuren, befindet sich in fortgeschrittenen Stadien des Baus einer neuen Produktionsstätte für oligonukleotide Arzneimittelsubstanzen mit einer zusätzlichen Kapazität von über 1,5 mol. Zu Beginn des Jahres wurde ein neuer 300 mmol Synthesizer erfolgreich in Betrieb genommen, wodurch die operativen Kapazitäten seiner mittleren Anlagen erhöht wurden. Es wird erwartet, dass Avecia an seinem Standort in Milford 2017 eine Herstellungskapazität zur cGMP-Synthese von Oligonukleotiden von nahezu 3 mol erreicht, einschließlich der Angliederung nachgelagerter Anlagen, wodurch Avecia zum größten cGMP-Oligonukleotidwerk der Welt wird.






Laut Präsident Detlef Rethage von Avecia sorgt die Erweiterung auf 300 mmol in 2016 gefolgt von dem neuen Werk mit einer Kapazität von über 1,5 mol dafür, dass Kunden oligonukleotide Arzneimittelsubstanzen fristgerecht erhalten, um wie geplant Programme in klinischen Studien voranzutreiben. „Avecia ist stolz darauf, dass wir dank unserer Erfahrung und Innovation bei Avecia die neuen Herstellungseinheiten innerhalb von Monaten anstatt von Jahren in Betrieb nehmen können”, sagte Rethage.

Mitarbeiter des neuen analytischen Entwicklungslabors sowie Büromitarbeiter beziehen derzeit ein neues Werk mit 600 m² in Marlboro, MA. Das Werk in Marlboro wurde ergänzt durch Nitto Avecia Pharma Services, ein neues Unternehmen, das infolge der kürzlichen Übernahme von Irvine Pharmaceutical Services (Irvine) und Avrio Biopharmaceuticals (Avrio) durch Avecia entstand. Durch Nitto Avecia Pharma Services mit Sitz in Irvine, CA, wurden die analytischen Fähigkeiten und die Unterstützung der Arzneimittelherstellung von Avecia wesentlich erhöht. Rethage äußerte: „Nitto Avecia Pharma Services ist die perfekte Ergänzung zu unserem Angebot im Bereich oligonukleotide Arzneimittelsubstanzen und ein wichtiger Schritt für unsere strategischen Wachstumspläne. Die Avecia Group bietet jetzt Herstellungs- und Entwicktlungsdienste an der Ostküste, Westküste und im Mittleren Westen in unserem Werk in Cincinatti an.”

Als Teil seines geplanten Wachstums erwartet Avecia die Schaffung vieler weiterer Vollzeitstellen in den nächsten drei Monaten. Die neuen Stellen beziehen sich auf Spezialisierungen in Mikrobiologie, analytischer Chemie, Herstellung, Qualitätssicherung und Technik. Weitere Informationen zu Stellenangeboten in Werken von Avecia finden Sie unter www.aveciacareers.com

INFORMATIONEN ZU NITTO AVECIA INC.

Nitto Avecia Inc. ist ein anerkannter, führender Hersteller von therapeutischen Nukleinsäuren und bietet Entwicklungsdienste in seinen Werken in Milford, Mass., Marlboro, Mass., und Cincinnati an. Die Angebote umfassen Dienstleistungen für Arzneimittel auf Basis von DNA, RNA und anderen Oligonukleotiden im Milligrammbereich in der präklinischen Phase bis zu 1000 kg nach Markteinführung. Weitere Informationen: www.Avecia.com. Nitto Avecia ist stolzes Mitglied der Nitto Group. Weitere Informationen: www.Nitto.com

INFORMATIONEN ZU AVECIA PHARMA SERVICES INC.

Nitto Avecia Pharma Services ist Ihre Komplettlösung für führende Vertragsentwicklungs- und Herstellungsdienste. Nitto Avecia Pharma Services unterstützt die pharmazeutischen, biopharmazeutischen und medizintechnischen Industrien mit einem Komplettpaket von cGMP-Diensten, darunter: Präformulierung/Formulierung, parenterale Herstellung, analytische Entwicklung, biopharmazeutische Entwicklung, strukturelle Chemie, analytische Chemie, Mikrobiologie, Stabilitätslagerung und Testen von Arzneimittelabgabesystemen. Mit drei modernsten Werken auf einem Campus in Irvine, CA, liefert Nitto Avecia Pharma Services mit erfahrenen Mitarbeitern und einer robusten Qualitätsinfrastruktur kundenorientierte Lösungen für Lifecyle-Management in den frühen Phasen bis nach der Markteinführung. Weitere Informationen siehe www.aveciapharma.com

Logo: http://photos.prnewswire.com/prnh/20161110/438178LOGO

Logo: http://photos.prnewswire.com/prnh/20161110/438179LOGO

SOURCE Nitto Avecia Inc.

Related Links


http://www.avecia.com


satprnews.com